Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.

[1]  G. Stone,et al.  A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem , 2012, Journal of the American College of Cardiology.

[2]  Jeroen J. Bax,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .

[3]  A. Kastrati,et al.  Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. , 2011, The New England journal of medicine.

[4]  M. Pansieri,et al.  High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. , 2011, Journal of the American College of Cardiology.

[5]  N. Schork,et al.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. , 2011, JAMA.

[6]  Deepak L. Bhatt,et al.  Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. , 2010, Journal of the American College of Cardiology.

[7]  D. Aradi,et al.  Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. , 2010, American heart journal.

[8]  S. Steinhubl,et al.  Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. , 2010, Journal of the American College of Cardiology.

[9]  J. Ruidavets,et al.  Relationship between time of day, day of the week and in-hospital mortality in patients undergoing emergency percutaneous coronary intervention. , 2009, Archives of cardiovascular diseases.

[10]  G. Stone,et al.  Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. , 2009, Journal of the American College of Cardiology.

[11]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[12]  R. Ferrari,et al.  Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance , 2009, Circulation.

[13]  B. Jilma,et al.  The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. , 2009, Thrombosis research.

[14]  A. Kastrati,et al.  Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. , 2009, Journal of the American College of Cardiology.

[15]  P. Morange,et al.  Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. , 2008, JACC. Cardiovascular interventions.

[16]  A. Kastrati,et al.  Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. , 2008, The New England journal of medicine.

[17]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[18]  A. Kastrati,et al.  Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment , 2007, Thrombosis and Haemostasis.

[19]  G. Davı̀,et al.  Platelet activation and atherothrombosis. , 2007, The New England journal of medicine.

[20]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[21]  M. Gawaz,et al.  Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease , 2007, Heart.

[22]  Adelaide,et al.  Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.

[23]  F. Neumann,et al.  Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. , 2006, Journal of the American College of Cardiology.

[24]  A. Kastrati,et al.  Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. , 2006, JAMA.

[25]  P. Gurbel,et al.  Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. , 2005, Journal of the American College of Cardiology.

[26]  A. Kastrati,et al.  A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. , 2004, The New England journal of medicine.

[27]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[28]  P Théroux,et al.  Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. , 1998, Circulation.

[29]  PierreThéroux,et al.  Platelet Activation With Unfractionated Heparin at Therapeutic Concentrations and Comparisons With a Low-Molecular-Weight Heparin and With a Direct Thrombin Inhibitor , 1998 .